Hillevax

Hillevax ROE

Delisted

The Return on Equity (ROE) of Hillevax (HLVX) as of Nov 20, 2026 is -95.33 %. In the previous year, Return on Equity (ROE) was -46.54 % — a change of 104.84% (lower).

ROE

-95.33 %

YoY

104.84%

Last updated:

In 2024, Hillevax's return on equity (ROE) was -95.33 %, a 104.84% increase from the -46.54 % ROE in the previous year.

The Hillevax ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
100.30 USD
Jan 1, 2020
76.88 USD
Jan 1, 2021
84.39 USD
Jan 1, 2022
-96.17 USD
Jan 1, 2023
-46.54 USD
Jan 1, 2024
-95.33 USD
The Hillevax ROE history
YEARROEYoY
-95.33 %+104.84%
-46.54 %-51.61%
-96.17 %-213.97%
84.39 %+9.76%
76.88 %-23.34%
100.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hillevax Stock analysis

What does Hillevax do? HilleVax, Inc. develops and commercializes novel vaccines, focusing on HIL-214, a bivalent virus-like particle (VLP) vaccine candidate for norovirus-induced acute gastroenteritis. The vaccine combines VLPs for norovirus genotypes GI.1 and GII.4 with an aluminum hydroxide adjuvant to enhance immune response. HIL-214 targets moderate-to-severe cases of norovirus infection, which causes symptoms like diarrhea, vomiting, and dehydration. The company's primary revenue stream will come from the future commercialization of HIL-214 after regulatory approval, with potential sales to healthcare providers and public health programs. Hillevax is one of the most popular companies on Eulerpool.

ROE Details

Decoding Hillevax's Return on Equity (ROE)

Hillevax's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Hillevax's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Hillevax's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Hillevax’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Hillevax stock

Return on Equity (ROE) of Hillevax is -95.33 % in 2024.

Return on Equity (ROE) of Hillevax changed from -46.54 % to -95.33 %, representing a 104.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Hillevax since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Hillevax with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Hillevax

All Key Metrics — Hillevax